The FDA has announced that the shortage of Eli Lilly's weight-loss and diabetes drugs, including Mounjaro and Zepbound, has officially ended. This resolution is significant as it directly affects the stock performance of Hims & Hers, which saw a notable decline following the announcement. With the supply of these GLP-1 medications stabilizing, Eli Lilly is expected to regain competitive ground against off-brand alternatives, which may suffer due to increased availability of the established drugs. The news has led to mixed reactions within the stock market, particularly for companies like Hims & Hers that may see their sales impacted as the market adjusts to the return of Eli Lilly's products.